This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Cell surface glycoprotein CD200 receptor 1.
.
Mouse | |
---|---|
Gene Name: | Cd200r1 |
Uniprot: | Q9ES57 |
Entrez: | 57781 |
Belongs to: |
---|
CD200R family |
CD200 R1; CD200 receptor 1; CD200R1; CD200RMOX2Rcell surface glycoprotein CD200 receptor 1; Cell surface glycoprotein OX2 receptor 1; cell surface glycoprotein receptor CD200; CRTR2; HCRTR2; MOX2 receptor; MOX2R; OX2RCD200 cell surface glycoprotein receptor
Mass (kDA):
35.505 kDA
Mouse | |
---|---|
Location: | 16|16 B4 |
Sequence: | 16; |
Expressed in granulocytes, monocytes, most T- cells and a subset of NK, NKT and B-cells (at protein level). Expressed in the spleen, lung, liver, testis, bone marrow, lymph nodes, spinal cord, kidney, uterus and small intestine. Expressed in mast and dendritic cells. Expressed in the lung of N. brasiliensis-infected mice.
We'll be discussing the products of Boster Bio. We'll also be discussing the Uses for the CD200R1Marker and REDExtract–N–AmpTM TissuePCR Kit.
The CD200R1 marker is a strong candidate for neuroprotection. It may protect against neuroinflammation, and neurotoxicity. The CD200R1 pathway is also a potential therapeutic target for Parkinson's. This article provides an overview of CD200R1 and its potential therapeutic uses. We also discuss the benefits of adding the CD200R1Marker to your research toolbox.
To determine the CD200R1 gene's function in the body, genomic DNA from the tail tissue was used. The REDExtract -N-Amp (tm) Tissue PCR Kit from Sigma-Aldrich was used to amplify genomic DNA. After DNA amplification, the gel was loaded with DNA ladder from Thermo Fisher Scientific. Midori green nucleic Acid staining solution is used to detect DNA. Images were taken with a UV Transilluminator. Integrated DNA Technology provided primers.
The REDExtract N-AMP(tm), Tissue PCR Kit can be used to extract DNA from a variety of cell types and amplify target genes via PCR. The innovative PCR extraction method eliminates the need for long digestions and homogenization steps. REDExtract–N–Amp PCR ReadyMix has an inert-and-tracking dye for easy loading PCR reactions onto agarose Gels for analysis.
We used conditional KO mice to either express the CD200R1 or CD200R1 genes to develop a vaccine against cancer. Mice were first given an agonist vaccine on day 2. Then, they were given a CD200 inhibitor and OVA protein vaccine on day 10. We then measured lymphocyte invasion six hours after the second vaccine to check for chemotaxis. We then tested for immunohistochemistry reactions to OVA protein and OVA + antagonist.
A CD200 inhibitor blocks CD200 activity in the immune system by binding with the CD200 activation protein on human monocytes. We have developed a mouse-based model to detect how the inhibitor inhibits antigen–specific CD8+T cell responses. We found that a CD200 antagonist reduces immune reactions by targeting CD200R. This antibody binds to CD200R.
RecombinantDNA can be introduced into a host cell to allow us to manipulate CD200R1 or CD200R1 gene transcription. This can be either mammalian (bacterial), yeast, or insect-cell-based. The DNA is introduced into the host cell by transfection, which can be either physical or biological. The exogenous gene is then integrated into the host cells genome and expressed in the host cells.
The present invention provides a way to express the desired protein in cells. The method involves integrating the DNA code for the CD200 inhibitor in a viral vector, and then transducing it into the host cell. The resulting antibody is then produced. The antibodies created are useful for studying different diseases. It is hoped that gene therapy can be used in humans for the improvement of patient's lives and to prevent them from developing unwelcome conditions.
Dopaminergic neurodegeneration results from MPTP-induced acute MPTPtoxicity. Researchers used CD200-deficient mice to study the role of CD200R1 signalling for dopaminergic neurodegeneration in the MPTP model. These experiments revealed that mice with CD200 deficiencies had higher levels of CD200R1 mRNA expression, but no changes in dopaminergic neurodegeneration.
CD200R1 and the Iba1 gene are co-localized in most cells. The CD200R1 gene may be a potential therapeutic target in Parkinson's (PD). It may also act as a neuroprotector by reducing neurotoxicity or activation of microglia. It is important to be familiar with the CD200R1 Marker's role in PD.
CD200R1 plays an important role in cancer immunotherapy. It can identify autoimmune disorders as well as immune-mediated diseases. It is frequently expressed in tumor cells and in stroma of patients with metastatic disease. It also interacts directly with CD200R1, allowing for the targeting of CD200-deficient patients. The following is a list of the various applications of the CD200R1 Marker.
The primary clinical parameter for patients with rectal tumors is the risk of recurrence. The risk of recurrence is high in patients with rectal cancer who have overexpressed CD200R1. This effect may occur independently of preoperative radiotherapy. It is important for you to know that tumor cells are highly expressing the CD200R1Marker. The results show that the CD200-CD200R1 signaling pathway can be involved in the progression of the disease.
It has been suggested that the CD200–CD200R1 pathway controls the immune response within the microglial population. The signaling pathway is present in both the physiological and pathological states of stroke and is important in regulating neuroinflammation. The CD200R1-CD200R1 interactions also play a role in the progression and development of immune responses after stroke injury. Although the mechanism is not clear, studies have shown that it inhibits inflammatory pathways.
CD200R1-mRNA was found within white matter and areas of demyelination and infiltration in the spinal cord. In the distal areas of the spinal chord, scattered CD200R1positive cells were also found. EAE is more severe in CD200/ mice than in wild-type mice. EAE can also occur in mice that overexpress CD200. Mice given anti-CD200 antibodies have severe EAE.
PMID: 10981966 by Wright G.J., et al. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function.
PMID: 12960329 by Wright G.J., et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.